Suhua Debuts Non-Invasive Transdermal Collagen in Nature Portfolio Journal

The collagen skincare sector is undergoing a massive paradigm shift, moving away from marketing-driven "brand self-assertion" toward rigorous, "evidence-based science."

On June 17, a landmark conference was held in Guangzhou, China, to unveil the clinical evidence for the world’s first non-invasive, topically applied recombinant humanized collagen. In an era where recombinant collagen technology is advancing at breakneck speed, a fundamental question that has dogged the beauty industry for decades has finally received a definitive scientific answer: Can topically applied macromolecular collagen truly penetrate the skin barrier to reach the dermis?

A groundbreaking study published in Scientific Reports, a Nature Portfolio journal, provides concrete, evidence-based medical proof. The research not only confirms the transdermal delivery of macromolecular humanized collagen but also introduces a clinical-grade validation methodology, signaling a new era of scientific credibility for the global cosmetics industry.

Why It Matters

For years, the global beauty industry has debated whether topically applied macromolecular collagen can actually penetrate the skin barrier to deliver real anti-aging benefits. By publishing peer-reviewed clinical evidence of non-invasive transdermal collagen, Chinese researchers are shifting the recombinant collagen market from marketing claims to rigorous, clinical-grade verification. This opens a lucrative "third path" between traditional topical skincare and invasive medical aesthetics. While many brands focus on rapid commercial expansion, such as leveraging TikTok beauty sales in Southeast Asia to capture immediate market share, others are playing the long game by investing heavily in deep scientific research to establish clinical credibility.

From "Concept Addition" to "Evidence-Based Efficacy": Elevating Verification Standards

For too long, the skincare industry has been trapped in a cycle of "marketing-driven science." Brands frequently package technical concepts in elaborate jargon, using Raman spectroscopy or brand-commissioned third-party reports to prove the mere "presence" of an ingredient. However, they fail to answer two critical questions: Where does the active ingredient go? and How long does it stay there? This level of self-certified proof serves marketing narratives rather than scientific truth.

To break this cycle, the research team behind Suhua C3 introduced clinical-grade, in vivo microscopic imaging—originally used for early cancer detection—to skincare efficacy testing. This technology offers five key advantages: it is in vivo, non-invasive, real-time, layered, and quantitative. Acting as a "GPS tracking system" for the skin, it allows researchers to track and quantify the exact penetration trajectory and retention time of collagen within the skin layers.

By introducing this methodology, the team has elevated the standard of skincare efficacy validation from simple brand self-assertion to clinical-grade imaging and peer-reviewed science. As beauty retail's future increasingly demands instant gratification and immediate product efficacy, having scientifically proven, high-performance ingredients becomes a critical competitive advantage for brands.

The "Three Clinical Questions": Redefining Gold Standards for Medical-Grade Collagen

Using this advanced in vivo imaging system, the study establishes three core dimensions—the "Three Clinical Questions"—to evaluate non-invasive transdermal collagen:

1. Where does it go? (Depth Evidence) The research shows that Suhua C3 recombinant humanized collagen precisely penetrates to a depth of 210±30μm, successfully crossing the dermal-epidermal junction (DEJ) to reach the active fibroblast zone in the upper dermis. This stands in stark contrast to traditional collagen, which merely sits on the epidermis, and is a prerequisite for triggering biological activity.

2. How long does it stay? (Duration Evidence) Penetration is only the first step; retention is key. Human clinical data reveals that the half-life of Suhua C3 collagen in the skin is 181.6% longer than that of standard collagen, remaining active for over 6 hours. This gives it the pharmacokinetic profile of a sustained treatment rather than a transient cosmetic, providing a solid scientific foundation for twice-daily home anti-aging regimens.

3. Who verified it? (Authority Evidence) All data originates from an independent clinical trial registered with the medical research registration system of China's National Health and Safety Information Platform (Registration No. MR-44-25-048541). The findings ultimately passed rigorous peer review to be published in Scientific Reports. This high-level chain of evidence eliminates any suspicion of brand bias and establishes undisputed scientific authority.

Divergent Technical Paths: "Molecular Penetration" vs. "Delivery Enhancement"

The study also highlights a fundamental divide in technical approaches. The industry's common "delivery enhancement" route (Route A) relies on external carriers like liposome encapsulation or chemical penetration enhancers. These methods often suffer from low transdermal efficiency and high skin irritation—classic symptoms of marketing-driven science.

In contrast, Suhua C3 utilizes a "molecular penetration" route (Route B), which represents a fundamental biological innovation. By retaining the C-terminal non-helical region and applying random mutation directed screening, researchers engineered a 20kDa macromolecular collagen that possesses an intrinsic, active ability to penetrate the skin.

Rather than relying on external carriers to "carry" the ingredient across, the collagen molecule itself is granted a "passport" to cross the skin barrier, marking a major leap from physical delivery to biological capability.

Cross-Species Validation and Strict Ethical Standards

The viability of any non-invasive transdermal collagen product hinges on safety and efficacy.

The research team constructed a rigorous cross-species validation framework. They first verified biocompatibility and penetration in mouse models. Once safety and efficacy were confirmed, they transitioned to human in vivo trials, securing the highest tier of evidence-based medical proof.

The entire research process, from animal testing to human trials, strictly adhered to approvals from both animal and human ethics committees and completed national clinical medical registration, establishing a robust safety and compliance barrier.

Expert Insights: Bridging the Gap Between Medical Aesthetics and Skincare

Leading scientific and medical aesthetics experts have highly praised this breakthrough.

Dr. Sun Zhongsheng, Director of the Plastic Surgery and Laser Center at Guangdong Second Provincial People's Hospital and co-author of the study, noted: "The debut of Suhua C3 collagen fills a massive market gap between Class II/III medical devices and Class III dermal fillers. It offers a brand-new, highly effective alternative for consumers who want powerful anti-aging results but are hesitant about invasive injections."

Dr. Shi Ge, Director of the Plastic Surgery Department at the Sixth Affiliated Hospital of Sun Yat-sen University, shared her clinical observations: "In my outpatient clinic, nine out of ten patients seeking anti-aging treatments ultimately opt out of injections. High costs, fear of pain, and potential risks are the primary barriers. The 'medical-grade, non-invasive topical application' represented by Suhua C3 collagen directly addresses this core consumer pain point."

Industry Leadership: From Scientific Discovery to Consumer Access

Li Jia, founder of Suhua and co-author of the study, reflected on the brand's scientific journey.

"Suhua first published our penetration experiments in 2022, prompting the industry to focus on transdermal absorption as a core challenge," Li said. "To bring truly effective collagen products to consumers, we spent three years completing this clinical-grade study. We didn't just prove that our collagen penetrates; we defined exactly how deep it goes and how long it stays. We continue to invest deeply in research so that consumers can make informed, confident choices."

Carving a "Third Path": Complementing and Substituting Medical Injections

Backed by solid clinical evidence, Suhua C3 collagen is carving out an entirely new category of "non-invasive transdermal collagen" positioned between traditional skincare and medical aesthetics. It solves the "zero efficacy" pain point of traditional topical cosmetics while offering a safe, effective, and sustainable anti-aging path for consumers who fear needles or are in between clinical aesthetic procedures.

This technology does not seek to replace medical injections, but rather to serve as an effective alternative and powerful complement. For mild to moderate aging, it serves as a standalone solution; for advanced aging, it can be used synergistically before and after clinical procedures to prolong and enhance the effects of injections.

This original research, led by a Chinese scientific team, not only sets a new global benchmark for transdermal collagen research but also signals that China is leading the world in the evidence-based application of recombinant humanized collagen.

References

Li J., Sun Z., Pang Y., Zhang G. In vivo assessment of collagen transdermal absorption in murine and human skin using photoacoustic microscopy. Scientific Reports (2026).

DOI: https://doi.org/10.1038/s41598-026-54420-4